Nevertheless, inhibition of UCPs, has to be considered as a strategy aimed at promoting the effects of other therapeutic agents, contributing to avoid the anti-apoptotic shield that UCP2 confers to cancer cells. The gene discussed is UCP2; the disease is cancer.